The present disclosure describes composition, methods, and systems associated with a genetically modified stem cell. The modified stem cell includes a reduced amount of Major Histocompatibility Complex II (MHC II) as compared to a corresponding wild-type cell. Further, the modified cell has decreased immunogenicity as compared to the corresponding wild-type cell.